4553 — Towa Pharmaceutical Co Income Statement
0.000.00%
Last trade - 00:00
- ¥136bn
- ¥302bn
- ¥209bn
- 44
- 73
- 95
- 86
2019 March 31st | 2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Yuho | Yuho | Yuho | Yuho | Yuho |
Standards: | JAS | JAS | JAS | JAS | JAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 105,104 | 110,384 | 154,900 | 165,615 | 208,859 |
Cost of Revenue | |||||
Gross Profit | 48,399 | 50,646 | 65,452 | 70,186 | 72,714 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 88,080 | 90,844 | 137,411 | 144,103 | 205,685 |
Operating Profit | 17,024 | 19,540 | 17,489 | 21,512 | 3,174 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 18,886 | 20,709 | 18,728 | 22,246 | 4,605 |
Provision for Income Taxes | |||||
Net Income After Taxes | 13,476 | 14,503 | 13,958 | 15,915 | 2,201 |
Net Income Before Extraordinary Items | |||||
Net Income | 13,476 | 14,503 | 13,958 | 15,915 | 2,201 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 13,468 | 14,496 | 13,944 | 15,912 | 2,201 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 240 | 228 | 321 | 298 | 172 |
Dividends per Share | |||||
Special Dividends per Share |